Human medicines European public assessment report (EPAR): Myalepta, metreleptin, Date of authorisation: 29/07/2018, Revision: 14, Status: Authorised

First webinar on new approach methodologies (NAMs) in ecotoxicology: State of the science for bioaccumulation, Online, from 10 September 2025, 14:00 (CEST) to 10 September 2025, 15:00 (CEST)

Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Exjade, deferasirox, Date of authorisation: 28/08/2006, Revision: 55, Status: Authorised

Human medicines European public assessment report (EPAR): Dasatinib Accord Healthcare, dasatinib, Date of authorisation: 26/07/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Fampyra, fampridine, Date of authorisation: 20/07/2011, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Spevigo, spesolimab, Date of authorisation: 09/12/2022, Revision: 3, Status: Authorised

Public statement on Esmya: Withdrawal of the marketing authorisation in the European Union

Opinion on medicine for use outside EU: Dapivirine Vaginal Ring 25 mg, dapivirine, Anti-HIV Agents, 23/07/2020 Positive opinion

Vaccine Monitoring Platform: List of EMA-funded studies